Doylestown, PA—aiaTranslations, a leader in life science translations, has been included in the Slator Life Science Translations report as a Main Global Provider of Language Services for the life sciences industry.
“Our inclusion in this report is important acknowledgement of our decades long expertise as language translation providers to the largest pharmaceutical companies,” said Molly Naughton, President of aiaTranslations.
Inclusion in the report by Slator, the most relevant source of language industry news and leader in Language Industry Intelligence, is a large honor. Besides outlining the drug development process and identifying the different content types arising from activities within the pharmaceutical industry, the Slator Report identifies the primary language services providers (LSPs) operating in clinical life sciences. According to Co-Founder and Managing Director of Slator, Florian Faes, states that for LSPs operating in clinical life sciences “…the ability to recruit and maintain a database of highly-skilled translators, project managers, and sales teams, as well as to invest in technology are factors that can heavily influence the relative success of LSPs competing in this space.”
Founded in 2010, aiaTranslations is the only full-service life sciences-specialized translation agency in the United States. With a global network of medical linguists, aiaTranslations can provide translations for projects ranging from clinical trials through commercialization and market research. While most translation companies focus on a variety of topics, aiaTranslations only recruits and retains top linguistic talent in the areas of medicine, healthcare, and pharmaceuticals, guaranteeing that every project and every document is worked on only by professional, subject matter expert translators.